Locally advanced cervical cancer (FIGO IIa2,IIb,III,IVa)
Conditions
Interventions
External beam radiotherapy: 50 Gy / 25 fractions Image-guided brachytherapy: 18-24 Gy / 3-4 fractions Chemotherapy: weekly cisplatin 40 mg / m2 for 5 weeks.
Sponsors
Gunma University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Histologically diagnosed adenocarcinoma, adeno-squamous cell carcinoma, or squamous cell carcinoma of uterine cervix. 2. International Federation of Gynecology and Obstetrics (FIGO) Stage IIa2 , IIb , III, or IVA disease 3. No para-aortic lymph nodes >= 1 cm in minimum diameter on CT images 4. The tumor had to be grossly measurable by MRI. 5. Tumor size is >= 4 cm in diameter 6. Age between 20 and 75 years 7. Performance status 0 - 2 8. Patients with no histories of prior chemotherapy or pelvic surgery for cervical cancer 9. Normal organ function (WBC >= 3000/mm3,Hb >= 9.5g/dl, Plt>= 100,000/mm3, T-Bil.<= 1.5mg/dl, AST(GOT) and ALT(GPT) <= 100IU/dl, Cre <= 1.5mg/dl, CCR >= 50ml/min, ECG normal or require no treatment 10. Informed consent is obtained
Exclusion criteria
Exclusion criteria: 1. Tumor invasion to gastro-intestinal tract. 2. Uncontrolled infection in pelvis 3. Rectal invasion History of pelvic radiotherapy 4. Severe complicating illness 5. Active double cancer 6. Possibility of pregnancy or lactation period 7. medical, psychological or others reason that primary doctor think ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pelvic disease progression-free rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival rate ,Local control rate, Incidence rate of acute adverse effects , Incidence rate of late adverse effect | — |
Countries
Japan
Contacts
Public ContactTatsuya Ohno
Gunma University Department of Radiation Oncology
Outcome results
None listed